Association between autism spectrum disorder and inflammatory bowel disease: A systematic review and meta-analysis / J. Y. KIM in Autism Research, 15-2 (February 2022)  

Public ISBD [article]  inAutism Research > 15-2 (February 2022) . - p.340-352 Titre : Association between autism spectrum disorder and inflammatory bowel disease: A systematic review and meta-analysis Type de document : Texte imprimé et/ou numérique Auteurs : J. Y. KIM, Auteur ; M. J. CHOI, Auteur ; S. HA, Auteur ; J. HWANG, Auteur ; A. KOYANAGI, Auteur ; E. DRAGIOTI, Auteur ; J. RADUA, Auteur ; L. SMITH, Auteur ; L. JACOB, Auteur ; G. S. DE PABLO, Auteur ; S. W. LEE, Auteur ; D. K. YON, Auteur ; T. THOMPSON, Auteur ; S. CORTESE, Auteur ; G. LOLLO, Auteur ; C. S. LIANG, Auteur ; C. S. CHU, Auteur ; P. FUSAR-POLI, Auteur ; Keun-Ah CHEON, Auteur ; J. I. SHIN, Auteur ; M. SOLMI, Auteur Article en page(s) : p.340-352 Langues : Anglais (eng) Mots-clés : Crohn's disease  autism spectrum disorder  inflammatory bowel disease  meta-analysis  ulcerative colitis Index. décimale : PER Périodiques Résumé : Children with autism spectrum disorder (ASD) are frequently diagnosed with co-occurring medical conditions including inflammatory bowel disease (IBD). To investigate the association, we conducted a systematic review registered in PROSPERO (ID:CRD42021236263) with a random-effects meta-analysis. We searched PubMed, Embase, and PsycInfo (last search on January 25, 2021), and manually searched relevant publications. We included observational studies measuring the association between ASD and IBD. The primary outcome was the association (odds ratio, OR) between ASD and later development of IBD. Sensitivity analyses were conducted by quality, confounding adjustment, and study design. We performed meta-regression analyses and assessed heterogeneity, publication bias, and quality of studies with the Newcastle-Ottawa Scale. Overall, we included six studies consisting of eight datasets, including over 11 million participants. We found that ASD was significantly associated with subsequent incident IBD (any IBD, OR = 1.66, 95% confidence interval[CI] = 1.25-2.21, p  En ligne : http://dx.doi.org/10.1002/aur.2656 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=450 [article] Association between autism spectrum disorder and inflammatory bowel disease: A systematic review and meta-analysis [Texte imprimé et/ou numérique] / J. Y. KIM, Auteur ; M. J. CHOI, Auteur ; S. HA, Auteur ; J. HWANG, Auteur ; A. KOYANAGI, Auteur ; E. DRAGIOTI, Auteur ; J. RADUA, Auteur ; L. SMITH, Auteur ; L. JACOB, Auteur ; G. S. DE PABLO, Auteur ; S. W. LEE, Auteur ; D. K. YON, Auteur ; T. THOMPSON, Auteur ; S. CORTESE, Auteur ; G. LOLLO, Auteur ; C. S. LIANG, Auteur ; C. S. CHU, Auteur ; P. FUSAR-POLI, Auteur ; Keun-Ah CHEON, Auteur ; J. I. SHIN, Auteur ; M. SOLMI, Auteur . - p.340-352. Langues : Anglais (eng) in Autism Research > 15-2 (February 2022) . - p.340-352 Mots-clés : Crohn's disease  autism spectrum disorder  inflammatory bowel disease  meta-analysis  ulcerative colitis Index. décimale : PER Périodiques Résumé : Children with autism spectrum disorder (ASD) are frequently diagnosed with co-occurring medical conditions including inflammatory bowel disease (IBD). To investigate the association, we conducted a systematic review registered in PROSPERO (ID:CRD42021236263) with a random-effects meta-analysis. We searched PubMed, Embase, and PsycInfo (last search on January 25, 2021), and manually searched relevant publications. We included observational studies measuring the association between ASD and IBD. The primary outcome was the association (odds ratio, OR) between ASD and later development of IBD. Sensitivity analyses were conducted by quality, confounding adjustment, and study design. We performed meta-regression analyses and assessed heterogeneity, publication bias, and quality of studies with the Newcastle-Ottawa Scale. Overall, we included six studies consisting of eight datasets, including over 11 million participants. We found that ASD was significantly associated with subsequent incident IBD (any IBD, OR = 1.66, 95% confidence interval[CI] = 1.25-2.21, p  En ligne : http://dx.doi.org/10.1002/aur.2656 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=450

Neurodiversity paradigms and their development across cultures: Some reflections in East Asian contexts / Tomoya HIROTA in Autism, 28-11 (November 2024)  

Public ISBD [article]  inAutism > 28-11 (November 2024) . - p.2685 - 2689 Titre : Neurodiversity paradigms and their development across cultures: Some reflections in East Asian contexts Type de document : Texte imprimé et/ou numérique Auteurs : Tomoya HIROTA, Auteur ; Keun-Ah CHEON, Auteur ; Meng-Chuan LAI, Auteur Article en page(s) : p.2685 - 2689 Langues : Anglais (eng) En ligne : https://dx.doi.org/10.1177/13623613241285678 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=537 [article] Neurodiversity paradigms and their development across cultures: Some reflections in East Asian contexts [Texte imprimé et/ou numérique] / Tomoya HIROTA, Auteur ; Keun-Ah CHEON, Auteur ; Meng-Chuan LAI, Auteur . - p.2685 - 2689. Langues : Anglais (eng) in Autism > 28-11 (November 2024) . - p.2685 - 2689 En ligne : https://dx.doi.org/10.1177/13623613241285678 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=537

Pharmacological and non-pharmacological interventions for irritability in autism spectrum disorder: a systematic review and meta-analysis with the GRADE assessment / Hangnyoung CHOI in Molecular Autism, 15 (2024)  

Public ISBD [article]  inMolecular Autism > 15 (2024) . - 7p. Titre : Pharmacological and non-pharmacological interventions for irritability in autism spectrum disorder: a systematic review and meta-analysis with the GRADE assessment Type de document : Texte imprimé et/ou numérique Auteurs : Hangnyoung CHOI, Auteur ; Jae Han KIM, Auteur ; Hee Sang YANG, Auteur ; Jong Yeob KIM, Auteur ; Samuele CORTESE, Auteur ; Lee SMITH, Auteur ; Ai KOYANAGI, Auteur ; Elena DRAGIOTI, Auteur ; Joaquim RADUA, Auteur ; Paolo FUSAR-POLI, Auteur ; Jae Il SHIN, Auteur ; Keun-Ah CHEON, Auteur ; Marco SOLMI, Auteur Article en page(s) : 7p. Langues : Anglais (eng) Mots-clés : Male  Humans  Female  GRADE Approach  Aripiprazole  Risperidone  Autism Spectrum Disorder  Autism spectrum disorder  Irritability  Meta-analysis  Randomized controlled trial  Systematic review  ADHD. PFP received honoraria/has been a consultant for Angelini, Menarini,  Lundbeck, and Sunovion. MS received honoraria/has been a consultant for ABBVie,  Angelini, Lundbeck, and Otsuka. Index. décimale : PER Périodiques Résumé : BACKGROUND: Numerous interventions for irritability in autism spectrum disorder (ASD) have been investigated. We aimed to appraise the magnitude of pharmacological and non-pharmacological interventions for irritability in ASD without any restrictions in terms of eligible interventions. METHODS: We systematically searched PubMed/MEDLINE, Scopus, and Web of Science until April 15, 2023. We included randomized controlled trials (RCTs) with a parallel design that examined the efficacy of interventions for the treatment of irritability in patients of any age with ASD without any restrictions in terms of eligible interventions. We performed a random-effects meta-analysis by pooling effect sizes as Hedges' g. We classified assessed interventions as follows: pharmacological monotherapy, risperidone plus adjuvant therapy versus risperidone monotherapy, non-pharmacological intervention, and dietary intervention. We utilized the Cochrane tool to evaluate the risk of bias in each study and the GRADE approach to assess the certainty of evidence for each meta-analyzed intervention. RESULTS: Out of 5640 references, we identified 60 eligible articles with 45 different kinds of interventions, including 3531 participants, of which 80.9% were males (mean age [SD] = 8.79 [3.85]). For pharmacological monotherapy, risperidone (Hedges' g -?0.857, 95% CI -?1.263 to -?0.451, certainty of evidence: high) and aripiprazole (Hedges' g -?0.559, 95% CI -?0.767 to -?0.351, certainty of evidence: high) outperformed placebo. Among the non-pharmacological interventions, parent training (Hedges' g -?0.893, 95% CI -?1.184 to -?0.602, certainty of evidence: moderate) showed a significant result. None of the meta-analyzed interventions yielded significant effects among risperidone?+?adjuvant therapy and dietary supplementation. However, several novel molecules in augmentation to risperidone outperformed risperidone monotherapy, yet from one RCT each. LIMITATIONS: First, various tools have been utilized to measure the irritability in ASD, which may contribute to the heterogeneity of the outcomes. Second, meta-analyses for each intervention included only a small number of studies and participants. CONCLUSIONS: Only risperidone, aripiprazole among pharmacological interventions, and parent training among non-pharmacological interventions can be recommended for irritability in ASD. As an augmentation to risperidone, several novel treatments show promising effects, but further RCTs are needed to replicate findings. Trial registration PROSPERO, CRD42021243965. En ligne : https://dx.doi.org/10.1186/s13229-024-00585-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=538 [article] Pharmacological and non-pharmacological interventions for irritability in autism spectrum disorder: a systematic review and meta-analysis with the GRADE assessment [Texte imprimé et/ou numérique] / Hangnyoung CHOI, Auteur ; Jae Han KIM, Auteur ; Hee Sang YANG, Auteur ; Jong Yeob KIM, Auteur ; Samuele CORTESE, Auteur ; Lee SMITH, Auteur ; Ai KOYANAGI, Auteur ; Elena DRAGIOTI, Auteur ; Joaquim RADUA, Auteur ; Paolo FUSAR-POLI, Auteur ; Jae Il SHIN, Auteur ; Keun-Ah CHEON, Auteur ; Marco SOLMI, Auteur . - 7p. Langues : Anglais (eng) in Molecular Autism > 15 (2024) . - 7p. Mots-clés : Male  Humans  Female  GRADE Approach  Aripiprazole  Risperidone  Autism Spectrum Disorder  Autism spectrum disorder  Irritability  Meta-analysis  Randomized controlled trial  Systematic review  ADHD. PFP received honoraria/has been a consultant for Angelini, Menarini,  Lundbeck, and Sunovion. MS received honoraria/has been a consultant for ABBVie,  Angelini, Lundbeck, and Otsuka. Index. décimale : PER Périodiques Résumé : BACKGROUND: Numerous interventions for irritability in autism spectrum disorder (ASD) have been investigated. We aimed to appraise the magnitude of pharmacological and non-pharmacological interventions for irritability in ASD without any restrictions in terms of eligible interventions. METHODS: We systematically searched PubMed/MEDLINE, Scopus, and Web of Science until April 15, 2023. We included randomized controlled trials (RCTs) with a parallel design that examined the efficacy of interventions for the treatment of irritability in patients of any age with ASD without any restrictions in terms of eligible interventions. We performed a random-effects meta-analysis by pooling effect sizes as Hedges' g. We classified assessed interventions as follows: pharmacological monotherapy, risperidone plus adjuvant therapy versus risperidone monotherapy, non-pharmacological intervention, and dietary intervention. We utilized the Cochrane tool to evaluate the risk of bias in each study and the GRADE approach to assess the certainty of evidence for each meta-analyzed intervention. RESULTS: Out of 5640 references, we identified 60 eligible articles with 45 different kinds of interventions, including 3531 participants, of which 80.9% were males (mean age [SD] = 8.79 [3.85]). For pharmacological monotherapy, risperidone (Hedges' g -?0.857, 95% CI -?1.263 to -?0.451, certainty of evidence: high) and aripiprazole (Hedges' g -?0.559, 95% CI -?0.767 to -?0.351, certainty of evidence: high) outperformed placebo. Among the non-pharmacological interventions, parent training (Hedges' g -?0.893, 95% CI -?1.184 to -?0.602, certainty of evidence: moderate) showed a significant result. None of the meta-analyzed interventions yielded significant effects among risperidone?+?adjuvant therapy and dietary supplementation. However, several novel molecules in augmentation to risperidone outperformed risperidone monotherapy, yet from one RCT each. LIMITATIONS: First, various tools have been utilized to measure the irritability in ASD, which may contribute to the heterogeneity of the outcomes. Second, meta-analyses for each intervention included only a small number of studies and participants. CONCLUSIONS: Only risperidone, aripiprazole among pharmacological interventions, and parent training among non-pharmacological interventions can be recommended for irritability in ASD. As an augmentation to risperidone, several novel treatments show promising effects, but further RCTs are needed to replicate findings. Trial registration PROSPERO, CRD42021243965. En ligne : https://dx.doi.org/10.1186/s13229-024-00585-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=538

The social responsiveness scale in relation to DSM IV and DSM5 ASD in Korean children / Keun-Ah CHEON in Autism Research, 9-9 (September 2016)  

Public ISBD [article]  inAutism Research > 9-9 (September 2016) . - p.970-980 Titre : The social responsiveness scale in relation to DSM IV and DSM5 ASD in Korean children Type de document : Texte imprimé et/ou numérique Auteurs : Keun-Ah CHEON, Auteur ; Jee-In PARK, Auteur ; Yun-Joo KOH, Auteur ; Jungeun SONG, Auteur ; Hyun-Joo HONG, Auteur ; Young-Kee KIM, Auteur ; Eun-Chung LIM, Auteur ; Hojang KWON, Auteur ; Mina HA, Auteur ; Myung-Ho LIM, Auteur ; Ki-Chung PAIK, Auteur ; John N. CONSTANTINO, Auteur ; Bennett L. LEVENTHAL, Auteur ; Young Shin KIM, Auteur Article en page(s) : p.970-980 Langues : Anglais (eng) Mots-clés : Korean social responsiveness scale  validity  reliability  DSM IV PDD  DSM5 ASD Index. décimale : PER Périodiques Résumé : The Social Responsiveness Scale (SRS) is an autism rating scales in widespread use, with over 20 official foreign language translations. It has proven highly feasible for quantitative ascertainment of autistic social impairment in public health settings, however, little is known about the validity of the reinforcement in Asia populations or in references to DSM5. The current study aims to evaluate psychometric properties and cross-cultural aspects of the SRS-Korean version (K-SRS).The study subjects were ascertained from three samples: a general sample from 3 regular education elementary schools (n=790), a clinical sample (n=154) of 6–12-year-olds from four psychiatric clinics, and an epidemiological sample of children with ASD, diagnosed using both DSM IV PDD, DSM5 ASD and SCD criteria (n=151). Their parents completed the K-SRS and the Autism Spectrum Screening Questionnaire(ASSQ). Descriptive statistics, correlation analyses and principal components analysis (PCA) were performed on the total population. Mean total scores on the K-SRS differed significantly between the three samples. ASSQ scores were significantly correlated with the K-SRS T-scores. PCA suggested a one-factor solution for the total population.Our results indicate that the K-SRS exhibits adequate reliability and validity for measuring ASD symptoms in Korean children with DSM IV PDD and DSM5 ASD. Our findings further suggest that it is difficult to distinguish SCD from other child psychiatric conditions using the K-SRS.This is the first study to examine the relationship between the SRS subscales and DSM5-based clinical diagnoses. This study provides cross-cultural confirmation of the factor structure for ASD symptoms and traits measured by the SRS. Autism Res 2016, 9: 970–980. En ligne : http://dx.doi.org/10.1002/aur.1671 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=294 [article] The social responsiveness scale in relation to DSM IV and DSM5 ASD in Korean children [Texte imprimé et/ou numérique] / Keun-Ah CHEON, Auteur ; Jee-In PARK, Auteur ; Yun-Joo KOH, Auteur ; Jungeun SONG, Auteur ; Hyun-Joo HONG, Auteur ; Young-Kee KIM, Auteur ; Eun-Chung LIM, Auteur ; Hojang KWON, Auteur ; Mina HA, Auteur ; Myung-Ho LIM, Auteur ; Ki-Chung PAIK, Auteur ; John N. CONSTANTINO, Auteur ; Bennett L. LEVENTHAL, Auteur ; Young Shin KIM, Auteur . - p.970-980. Langues : Anglais (eng) in Autism Research > 9-9 (September 2016) . - p.970-980 Mots-clés : Korean social responsiveness scale  validity  reliability  DSM IV PDD  DSM5 ASD Index. décimale : PER Périodiques Résumé : The Social Responsiveness Scale (SRS) is an autism rating scales in widespread use, with over 20 official foreign language translations. It has proven highly feasible for quantitative ascertainment of autistic social impairment in public health settings, however, little is known about the validity of the reinforcement in Asia populations or in references to DSM5. The current study aims to evaluate psychometric properties and cross-cultural aspects of the SRS-Korean version (K-SRS).The study subjects were ascertained from three samples: a general sample from 3 regular education elementary schools (n=790), a clinical sample (n=154) of 6–12-year-olds from four psychiatric clinics, and an epidemiological sample of children with ASD, diagnosed using both DSM IV PDD, DSM5 ASD and SCD criteria (n=151). Their parents completed the K-SRS and the Autism Spectrum Screening Questionnaire(ASSQ). Descriptive statistics, correlation analyses and principal components analysis (PCA) were performed on the total population. Mean total scores on the K-SRS differed significantly between the three samples. ASSQ scores were significantly correlated with the K-SRS T-scores. PCA suggested a one-factor solution for the total population.Our results indicate that the K-SRS exhibits adequate reliability and validity for measuring ASD symptoms in Korean children with DSM IV PDD and DSM5 ASD. Our findings further suggest that it is difficult to distinguish SCD from other child psychiatric conditions using the K-SRS.This is the first study to examine the relationship between the SRS subscales and DSM5-based clinical diagnoses. This study provides cross-cultural confirmation of the factor structure for ASD symptoms and traits measured by the SRS. Autism Res 2016, 9: 970–980. En ligne : http://dx.doi.org/10.1002/aur.1671 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=294

---

1 (1 - 4 / 4)